±³À°¾È³»

2014³âµµ NAMSA ÄÁÆÛ·±½º

  • °úÁ¤ºÐ·ù :  ÃʱÞ
  • ±³À°ÀÏÁ¤ :  2014-04-17
  • ±³À°ÀÚ°Ý :  ÀÇ·á±â±â °ü·Ã ¾÷ü
  • ¸ðÁýÀοø :  20¸í Ãß°¡¸ðÁý (Á¶ÇÕȸ¿ø»ç ¿ì¼±)
  • ±³ À° ºñ :  ±³À°ºñ ¹«·á
  • ÀÌ·Ð/½Ç½ÀºñÀ² :  

±³À°°³¿ä

1. Conference

 

- ÀÏ ½Ã : 2014³â 4¿ù 17ÀÏ (¸ñ) / (Àå ¼Ò : ¿µµîÆ÷ Çѱ¹È­ÇÐÀ¶ÇÕ½ÃÇ迬±¸¿ø  ´ë°­ÀǽÇ)

 

- Âü¿©Àοø : 70¿©¸í (20¸í Ãß°¡¸ðÁý) / ±³À°ºñ ¹«·á

 

- Á¢¼ö¹æ¹ý : www.medihrd.or.krȨÆäÀÌÁö °¡ÀÔ ÈÄ Á¢¼ö (¿Â¶óÀÎÁ¢¼ö¸¸ ¹Þ½À´Ï´Ù.)

 

¹® ÀÇ : ¸ÞµðÆÛÆ® ³ª¿ëÇÏ 02-921-6103, 010-7353-3773, yongha@medipert.com

                         ¹ÚÁø¿µ 02-921-6101, jyp@medipert.co

 

▸ ±³À°Àå¼Ò : ¼­¿ïƯº°½Ã ¿µµîÆ÷±¸ ¹öµå³ª·ç·Î 155 (¿µµîÆ÷µ¿8°¡ 88-2¹øÁö) 

                  (Çѱ¹È­ÇÐÀ¶ÇÕ½ÃÇ迬±¸¿ø)

 

▸ ÁöÇÏö : 2È£¼± ´ç»ê¿ª ÇÏÂ÷ 6¹øÃⱸ µµº¸ 7ºÐ°Å¸®
                 9È£¼± ´ç»ê¿ª ÇÏÂ÷ 8¹øÃⱸ µµº¸ 5ºÐ°Å¸®

 

▸  ¹ö  ½º  : 5714,  605,  6514,  6619,  6623,  6633,  760,  9707

               (»ï¼º·¡¹Ì¾È¾ÆÆÄÆ® ¾Õ ÇÏÂ÷)  

 

 

▸±³À°±â°£ Áß ÁÖÂ÷°¡ ºÒ°¡ÇÏ¿À´Ï ´ëÁß±³ÅëÀ» ÀÌ¿ëÇÏ¿© ±³À°¿¡ Âü¼®ÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.

 

ÁÖ °ü : NAMSA, Çѱ¹ÀÇ·á±â±â°ø¾÷Çùµ¿Á¶ÇÕ / ÁÖ ÃÖ : ¸ÞµðÆÛÆ® (NAMSA Agent in KOREA)

±³À°ÀÏÁ¤Ç¥

- ÄÁÆÛ·±½º ÁÖÁ¦ ¹× ½Ã°£Ç¥ ( ¡Ø °­ÀÇ´Â ¿µ¾î·Î¸¸ ÁøÇàµË´Ï´Ù. )

ÀÏÀÚ

(Date)

½Ã°£(Time)

³»¿ë(Agenda)

ÁøÇà/°­»ç

(Moderator/Speaker)

04/17

(¸ñ)

10:00 10:50

Thinking Globally During Product Development

Dr. Seth Goldenberg, Medical Research Scientist, NAMSA

11:00 11:50

US FDA medical device regulation and product registration

Dr. Seth Goldenberg, Medical Research Scientist, NAMSA

12:00 13:30

Lunch Break

13:30 14:20

Methods and interpretation of pre-clinical performance studies

Dr. Jean-Pierre Boutrand, VP of Global Sales, NAMSA

 

14:30 15:20

Biological evaluation and regulation of medical devices in the European Union Update on the EU Med. Dev. New Regulation in the EU

Dr. Jean-Pierre Boutrand, VP of Global Sales, NAMSA

15:30 16:20

Chinese CFDA medical device regulation and special biocompatibility requirements

An Liu, GM of NAMSA China, NAMSA

¾È³»»çÇ×

 

À§Ä¡¾È³»